NASDAQ:JANX

Janux Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy JANX

*Your capital is at risk

$13.59

-0.190 (-1.38%)

At Close: Jun 03, 2026

Janux Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 90.43. In total, the insiders bought 3.66M and sold 57.74K JANX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	90.43
● Buy	3.66M shares
● Sell	57.74K shares
83% Buy Activity Strong Negative Correlation
Buy Signal High Confidence Jun 01, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 90.43. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (83% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 01, 2025 Sell	Common Stock S-Sale	Meyer Andrew Hollman Chief Business Officer	Officer	633 Value: $21.2K
Nov 14, 2025 Buy	Stock Option (right to buy) M-Exempt	Meyer Andrew Hollman Chief Business Officer	Officer	3 333 Value: $35.3K
Nov 14, 2025 Buy	Common Stock M-Exempt	Meyer Andrew Hollman Chief Business Officer	Officer	3 333 Value: $35.3K
Nov 14, 2025 Sell	Common Stock S-Sale	Meyer Andrew Hollman Chief Business Officer	Officer	3 333 Value: $100.0K
Oct 28, 2025 Buy	Stock Option (right to buy) M-Exempt	Meyer Andrew Hollman Chief Business Officer	Officer	9 999 Value: $42.1K
Oct 28, 2025 Buy	Common Stock M-Exempt	Meyer Andrew Hollman Chief Business Officer	Officer	9 999 Value: $42.1K
Oct 28, 2025 Buy	Common Stock M-Exempt	Meyer Andrew Hollman Chief Business Officer	Officer	6 666 Value: $70.6K
Oct 28, 2025 Buy	Stock Option (right to buy) M-Exempt	Meyer Andrew Hollman Chief Business Officer	Officer	6 666 Value: $70.6K
Oct 28, 2025 Sell	Common Stock S-Sale	Meyer Andrew Hollman Chief Business Officer	Officer	16 665 Value: $501.0K
Jun 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Ra Capital Management, L.p.	Director	11 667 Value: $297.0K
Jun 11, 2025 Buy	Common Stock A-Award	Ra Capital Management, L.p.	Director	3 750 Value: $95.5K
Jun 11, 2025 Buy	Stock Option (right to buy) A-Award	Barrett Ronald W Director	Director	11 667 Value: $297.0K
Jun 11, 2025 Buy	Common Stock A-Award	Barrett Ronald W Director	Director	3 750 Value: $95.5K
Jun 11, 2025 Buy	Common Stock A-Award	Capps Vickie L Director	Director	3 750 Value: $95.5K
Jun 11, 2025 Buy	Stock Option (right to buy) A-Award	Capps Vickie L Director	Director	11 667 Value: $297.0K
Jun 11, 2025 Buy	Stock Option (right to buy) A-Award	Dobmeier Eric Director	Director	11 667 Value: $297.0K
Jun 11, 2025 Buy	Common Stock A-Award	Dobmeier Eric Director	Director	3 750 Value: $95.5K
Jun 11, 2025 Buy	Common Stock A-Award	Gujrathi Sheila Director	Director	3 750 Value: $95.5K
Jun 11, 2025 Buy	Stock Option (right to buy) A-Award	Gujrathi Sheila Director	Director	11 667 Value: $297.0K
Jun 11, 2025 Buy	Stock Option (right to buy) A-Award	Hernday Natasha Director	Director	11 667 Value: $297.0K
Jun 11, 2025 Buy	Common Stock A-Award	Hernday Natasha Director	Director	3 750 Value: $95.5K
Jun 11, 2025 Buy	Stock Option (right to buy) A-Award	Mcnulty Alana B. Director	Director	11 667 Value: $297.0K
Jun 11, 2025 Buy	Common Stock A-Award	Mcnulty Alana B. Director	Director	3 750 Value: $95.5K
Jun 11, 2025 Buy	Stock Option (right to buy) A-Award	Simson Jake Director	Director	11 667 Value: $297.0K
Jun 11, 2025 Buy	Common Stock A-Award	Simson Jake Director	Director	3 750 Value: $95.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT JANUX THERAPEUTICS, INC.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a ...

Read Full Profile Here